Industry Veteran Andy Balo Joins Glucotrack

Andy Balo, a veteran with decades of experience in regulatory, clinical, and quality roles within the medical technology industry, has joined Glucotrack’s Board of Directors. Balo, who retired from Dexcom in March 2024 after 22 years as Executive Vice President of Clinical, Global Access, and Medical Affairs, played a pivotal role in shaping Dexcom’s success, overseeing numerous global regulatory submissions and clinical trials for glucose monitoring systems.

Before his time at Dexcom, Balo held key leadership positions at companies like St. Jude Medical, Baxter, Pacesetter, and Endocardial Solutions, focusing on regulatory and clinical strategies. His industry expertise has also been recognized by his service on several U.S. Food and Drug Administration panels.

Welcoming Balo, Glucotrack CEO Paul Goode expressed confidence in his leadership, citing Balo’s deep understanding of diabetes and cardiovascular technologies. Balo’s involvement comes at a crucial time as Glucotrack prepares to enter human clinical trials for its implantable continuous blood glucose monitoring system.

Balo, excited to join Glucotrack, highlighted the potential of the company’s continuous blood glucose monitor, which combines diabetes and cardiovascular technologies in an innovative way. Glucotrack’s CBGM system, designed for long-term use, offers continuous blood glucose measurement without the need for a wearable component and requires minimal calibration.